Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» sparsentan
sparsentan
Travere’s Kidney Disease Drug Narrowly Misses Phase III Endpoint, Stock Tanks
BioSpace
Thu, 09/21/23 - 06:34 pm
Travere Therapeutics
kidney disease
sparsentan
Filspari
clinical trials
Travere’s FSGS therapy trial fails to meet primary efficacy endpoint
Clinical Trials Arena
Tue, 05/2/23 - 11:30 am
Travere Therapeutics
sparsentan
focal segmental glomerulosclerosis
clinical trials
Travere fails to convince regulators to consider accelerated approval for a rare kidney disease — again
Endpoints
Thu, 08/4/22 - 10:56 am
Travere Therapeutics
Martin Shkreli
sparsentan
FDA
kidney disease
Retrophin (With Help From Martin Shkreli) Advances Drug for Rare Kidney Disease
TheStreet.com
Wed, 09/7/16 - 10:04 am
Retrophin
Martin Shkreli
sparsentan
kidney disease
focal segmental glomerulosclerosis